ORYZ.F Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Oryzon Genomics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.01 |
| 52 Week High | €2.26 |
| 52 Week Low | €1.41 |
| Beta | 0.65 |
| 11 Month Change | 4.15% |
| 3 Month Change | 4.15% |
| 1 Year Change | 18.24% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORYZ.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.1% | 4.0% | 2.0% |
| 1Y | 18.2% | 18.0% | 32.4% |
Return vs Industry: ORYZ.F matched the US Biotechs industry which returned 18% over the past year.
Return vs Market: ORYZ.F underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| ORYZ.F volatility | |
|---|---|
| ORYZ.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ORYZ.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ORYZ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 44 | Carlos Manuel Arjol | www.oryzon.com |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.
Oryzon Genomics S.A. Fundamentals Summary
| ORYZ.F fundamental statistics | |
|---|---|
| Market cap | US$100.28m |
| Earnings (TTM) | -US$4.56m |
| Revenue (TTM) | US$15.83m |
6.3x
P/S Ratio-22.0x
P/E RatioIs ORYZ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORYZ.F income statement (TTM) | |
|---|---|
| Revenue | US$15.83m |
| Cost of Revenue | US$271.80k |
| Gross Profit | US$15.56m |
| Other Expenses | US$20.11m |
| Earnings | -US$4.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.072 |
| Gross Margin | 98.28% |
| Net Profit Margin | -28.78% |
| Debt/Equity Ratio | 20.8% |
How did ORYZ.F perform over the long term?
See historical performance and comparison